BeiGene — CureCurrent

How to interpret these research links

Connected source records

The exact organization name BeiGene appears in 33 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials33

Recruiting shown5

Roles2

SourceClinicalTrials.gov

Clinical trials

33 shown

A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid ArthritisNCT07100938 · lead sponsor · 2025-08-21

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsNCT06257264 · lead sponsor · 2024-03-11

ACTIVE_NOT_RECRUITING

Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung CancerNCT06091943 · lead sponsor · 2023-11-16

A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung CancerNCT06029127 · lead sponsor · 2023-10-23

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung CancerNCT05577702 · lead sponsor · 2023-03-08

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerNCT05635708 · lead sponsor · 2023-03-07

ACTIVE_NOT_RECRUITING

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerNCT05014815 · lead sponsor · 2021-11-16

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT04921358 · lead sponsor · 2021-07-27

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung CancerNCT04952597 · lead sponsor · 2021-07-15

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung CancerNCT04866017 · lead sponsor · 2021-06-17

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerNCT04746924 · lead sponsor · 2021-05-24

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)NCT04379635 · lead sponsor · 2020-05-29

ACTIVE_NOT_RECRUITING

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without TislelizumabNCT04276493 · lead sponsor · 2020-03-23

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsNCT04215978 · lead sponsor · 2020-01-30

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerNCT04005716 · lead sponsor · 2019-07-22

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination DeficiencyNCT03712930 · lead sponsor · 2019-02-05

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerNCT03594747 · lead sponsor · 2018-07-30

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung CancerNCT03663205 · lead sponsor · 2018-07-23

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in ChinaNCT03575065 · lead sponsor · 2018-06-22

Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT03358875 · lead sponsor · 2017-11-30

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung CancerNCT03432598 · lead sponsor · 2017-08-24

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid TumorsNCT03150810 · lead sponsor · 2017-06-28

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid TumorsNCT03333915 · lead sponsor · 2016-12-21

A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLCNCT07815223 · collaborator · 2025-11-04

tislelizUMaB in canceR Patients With molEcuLar residuaL DiseaseNCT06332274 · collaborator · 2025-04-16

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)NCT05431270 · collaborator · 2022-08-11

MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLCNCT05286957 · collaborator · 2022-06-20

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerNCT04221542 · collaborator · 2020-03-04

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLCNCT06456138 · collaborator · 2024-07-01

NOT_YET_RECRUITING

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerNCT05189457 · collaborator · 2022-01-25

ACTIVE_NOT_RECRUITING

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsNCT04577963 · collaborator · 2021-08-09

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsNCT04579757 · collaborator · 2021-03-05

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung CancerNCT03745222 · collaborator · 2019-05-22

Drugs studied in this sponsor's trials

21 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing BeiGene as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

tislelizumab20

carboplatin8

cisplatin6

docetaxel6

pemetrexed6

paclitaxel5

etoposide2

gemcitabine2

tislelizumab RxCUI 2677426 · Lead sponsor in 14 linked trial(s) · 2 currently recruiting 20 trials carboplatin RxCUI 40048 · Lead sponsor in 8 linked trial(s) · 0 currently recruiting 8 trials cisplatin RxCUI 2555 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 6 trials docetaxel RxCUI 72962 · Lead sponsor in 4 linked trial(s) · 1 currently recruiting 6 trials pemetrexed RxCUI 68446 · Lead sponsor in 5 linked trial(s) · 1 currently recruiting 6 trials paclitaxel RxCUI 56946 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 5 trials etoposide RxCUI 4179 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials gemcitabine RxCUI 12574 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 2 trials abiraterone RxCUI 1100072 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial capecitabine RxCUI 194000 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cisplatin Injection RxCUI 1736853 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial durvalumab RxCUI 1919503 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial enzalutamide RxCUI 1307298 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial fruquintinib RxCUI 2670179 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial fulvestrant RxCUI 282357 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial oxaliplatin RxCUI 32592 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paclitaxel Injection RxCUI 1663181 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pembrolizumab RxCUI 1547545 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pemetrexed disodium RxCUI 282443 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial temozolomide RxCUI 37776 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial trametinib RxCUI 1425099 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor23

collaborator10

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.